Spending User Fees In The US: Biomarker Research, Drug-Device Combos?
This article was originally published in SRA
Executive Summary
Even though the technical negotiations between the US Food and Drug Administration and representatives from the biopharmaceutical industry are just getting underway this month in earnest for the sixth round of the Prescription Drug User Fee Act (PDUFA VI), some regulators and drug makers already have their eyes set on how the money should be spent, or at least, some of it.